LYSOSOMAL THERAPEUTICS INC. logo

Lysosomal Therapeutics, Inc.

Lysosomal Therapeutics, Inc. (LTI) is research and development based company developing small molecule in the field of neurodegeneration and Lysosomal Storage Disorders.

LTI was co-founded by Kees Been, Edmund Sybertz, Peter Wirth, J.D., Bob Carpenter and Henri Termeer who is dedicated to innovative small-molecule for lysosome-based genetic disorders and neurodegenerative diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.lysosomaltx.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
19 Blackstone Street MA 02139
Cambridge
United States
Email
Contact Number
+1 617-714-9620

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/lysosomal-therapeutics-inc.” connections=”true” suffix=””]

LTI is leveraging its expertise in lysosomal biology to develop novel small molecules to be used in the treatment of various neuro degenerative diseases. Its lead program, the GCase agonist, was discovered by the National Institute of Health. LTI has the exclusive license to this intellectual property.

Jan 2017, Allergan plc has purchased an exclusive option right to acquire Lysosomal Therapeutics, Inc. Under the option agreement, Allergan purchased an option right directly from LTI shareholders to acquire LTI following completion of a Phase 1b trial

In Feb 2015, LTI raised US$20 Mn in Series A Financing from its key investors; Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund.

In 2014, LTI received The Michael J. Fox Foundation grant for developing a drug and required biomarker assay, to correct the biochemical deficit caused by the gene for Gauchers disease that also significantly increased risk of Parkinsons disease.